Sommer Frank
Department of Men's Health & Department of Urology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, DE-20246 Hamburg, Germany.
Expert Opin Drug Metab Toxicol. 2005 Aug;1(2):295-301. doi: 10.1517/17425255.1.2.295.
Erectile dysfunction (ED) is a widespread, age-related medical condition that affects > 50% of men aged 40 - 70 years. Pharmacotherapy with orally available phosphodiesterase 5 (PDE5) inhibitors offers a convenient and simple approach to treatment. Results of numerous clinical trials have demonstrated significant efficacy in restoring the ability to achieve and sustain an erection, and adverse side effects are generally mild-to-moderate in severity. Vardenafil is a highly selective, potent PDE5 inhibitor developed for the treatment of ED. The potency and selectivity of vardenafil for PDE5 and other PDE isoforms have been evaluated in vitro and in vivo and compared with other compounds in the class. This review will discuss the findings of biochemical, in vitro and in vivo experiments that indicate the superior potency and high selectivity of vardenafil.
勃起功能障碍（ED）是一种普遍存在的、与年龄相关的医学病症，影响超过50%的40 - 70岁男性。口服磷酸二酯酶5（PDE5）抑制剂进行药物治疗提供了一种便捷简单的治疗方法。众多临床试验结果表明，在恢复勃起和维持勃起能力方面具有显著疗效，且不良反应一般为轻至中度。伐地那非是一种为治疗ED而研发的高选择性、强效PDE5抑制剂。已在体外和体内评估了伐地那非对PDE5及其他PDE亚型的效力和选择性，并与该类中的其他化合物进行了比较。本综述将讨论生化、体外和体内实验的结果，这些结果表明伐地那非具有卓越的效力和高选择性。
